Acutherapy for Joint Pain in Breast Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should not have used adjuvant aromatase inhibitors for more than 14 days before the study.
What data supports the effectiveness of the treatment Acutherapy for joint pain in breast cancer?
Is acupuncture safe for treating joint pain in breast cancer patients?
What is the purpose of this trial?
This clinical trial evaluates if in-person acupuncture or virtual acupressure therapy prevents aromatase inhibitor-associated joint pain in Non-Hispanic Black postmenopausal women with stage I-III (early-stage) hormone receptor positive (HR+) breast cancer. Aromatase inhibitors (AI) are medications that prevent the formation of the hormone estrogen. They are used in the treatment of postmenopausal women who have hormone-dependent breast cancer. AI therapy prolongs life among patients with early-stage HR+ breast cancer. Many postmenopausal women stop AI therapy early due to debilitating joint pain (arthralgias). Non-Hispanic Black women are more likely to experience side effects and stop their hormonal therapy compared to Non-Hispanic white women. Acupuncture therapy involves inserting thin needles through the skin at specific points on the body to control pain. Acupressure therapy uses the application of pressure or localized massage to specific sites on the body to control symptoms such as pain. Acupuncture and acupressure are types of complementary and alternative medicine. Undergoing in-person acupuncture or participating in virtual acupressure may prevent AI-associated arthralgias (AIAA) in Non-Hispanic Black postmenopausal women with early-stage HR+ breast cancer.
Research Team
Demetria Smith-Graziani, MD,MPH
Principal Investigator
Emory University Hospital/Winship Cancer Institute
Eligibility Criteria
This trial is for Non-Hispanic Black postmenopausal women with stage I-III hormone receptor positive breast cancer who are taking aromatase inhibitors. It aims to help those suffering from joint pain due to their medication. Participants should not have started AI therapy more than a month ago and must be able to attend in-person or virtual sessions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either in-person acupuncture or virtual acupressure therapy while receiving standard of care AI therapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Acutherapy
Find a Clinic Near You
Who Is Running the Clinical Trial?
Emory University
Lead Sponsor
Bristol-Myers Squibb
Industry Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania
National Cancer Institute (NCI)
Collaborator